<DOC>
	<DOCNO>NCT01047943</DOCNO>
	<brief_summary>The clinical assessment patient plaque-type psoriasis perform open , intrapatient comparison 0.2 % STA-21 vehicle ( Vaseline ) alone within 2 week period .</brief_summary>
	<brief_title>STA-21 Topical Efficacy Psoriasis</brief_title>
	<detailed_description>Two discrete psoriatic lesion similar size ( approximately coin-sized ) clinical severity select patient . Clinical assessment psoriatic lesion severity perform baseline 1 2 ( end treatment ) use score erythema , induration , scale scale 0-4 two observer . Since STA-21 inhibits Stat3 activation , essential disease activity psoriasis , topical application 0.2 % STA-21 Vaseline improve psoriasis two week .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>A history plaque psoriasis minimum 2 year . In good general health , evidence blood , renal function , liver function test conduct commence study . Patients childbearing age agree continue use birth control duration study . Men woman 20 80 year old . Chronic plaque psoriasis involve &gt; 40 % body surface . Pustular generalized erythrodermic psoriasis . Use medication might affect psoriasis study Systemic therapy psoriasis within 60 baseline . UV therapy within 21 baseline . Topical therapy within 14 baseline . Positive HIV , hepatitis B , hepatitis C. Clinically significant laboratory abnormality blood , renal function , liver function . Lactating , pregnant , plan become pregnant . Participation another clinical trial last 30 d. Unwillingness comply study protocol . Any condition opinion investigator could compromise study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>